[Treatment of severe arterial hypertension with propyldazine (ISF 2123) associated with a diuretic and a beta-blocking agent].
作者信息
Angelino P F, Lavezzaro G, Carnovali M
出版信息
Minerva Cardioangiol. 1979 Mar;27(3):113-8.
PMID:37462
Abstract
摘要
相似文献
1
[Treatment of severe arterial hypertension with propyldazine (ISF 2123) associated with a diuretic and a beta-blocking agent].
Minerva Cardioangiol. 1979 Mar;27(3):113-8.
2
Antihypertensive efficacy of a new long acting hydralazine like vasodilator, ISF 2469 in combination with a betablocker and a diuretic.
Int J Clin Pharmacol Biopharm. 1979 Oct;17(10):380-5.
3
Evaluation and treatment of the hypertensive patient.
Prim Care. 1983 Mar;10(1):3-20.
4
[Evaluation of combination drug therapy in the malignant phase of arterial hypertension].
Srp Arh Celok Lek. 1983 Jul;111(7):905-18.
5
[Drug therapy for arterial hypertension].
Soins. 1982 Feb;27(4):25-35.
6
7
[Basic principles and methods of treating hypertension].
Vestn Akad Med Nauk SSSR. 1981(9):50-9.
8
[Calcium antagonists in the treatment of arterial hypertension].
Klin Med (Mosk). 1985 Nov;63(11):9-15.
9
[Antihypertensive pharmacotherapy with the vasodilators captopril and endralazine].
Schweiz Med Wochenschr. 1985 Jul 9;115(27-28):939-44.
10
[Fixed-dose combination therapy: reduction of side effects with enhanced tolerance and antihypertensive efficacy].
Rev Esp Cardiol. 1999;52 Suppl 3:59-72.
Zotero 插件